Casey McPherson | CEO
AlphaRose Therapeutics Inc.
Casey McPherson is an accomplished drug developer, entrepreneur and singer-songwriter based in Austin, Texas. Known for his two #10 US hits, he shifted his focus to rare disease commercial development after his daughter Rose was diagnosed with a rare genetic condition. In 2020, he founded the To Cure A Rose Foundation and later founded RareLabs, a lab dedicated to developing pre-clinical treatments for rare diseases with 20 programs in the pipeline, and 8 new treatments discovered. In 2023, he launched AlphaRose Therapeutics, a platform to commercialize rare genetic disease therapeutics at scale. Casey continues to build solutions for precision medicine while enjoying life with his two daughters.
Appearances:
Day 2 - World Orphan Drug Congress USA 2026 @ 14:30
Doing Well Through Doing Good: Investing in Rare Disease Drugs
Orphan disease drug development and commercialization is often fragmented - with an inefficient clinical development model, an incorrect way of measuring Return of Investment and a commercial model that is often unattractive vis-a-vis other disease states. Imagine an approach where there is access to knowledge, infrastructure and mission-dedicated evergreen capital to systematically develop new medicines for orphan diseases. Imagine an investment vehicle with dual objectives: Return on mission- curing rare diseases and Return on capital: Making money while doing that! In this panel, we will discuss both the operational and capitalization novelties in this new model. Capital allocations from foundations and family offices / UHNWIs can enable such a construct, along with an infrastructure support system from hospitals, scientists, drug manufacturers.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events